401.80
price up icon2.44%   9.56
pre-market  Pre-mercato:  405.00   3.20   +0.80%
loading
Precedente Chiudi:
$392.24
Aprire:
$388.68
Volume 24 ore:
1.78M
Relative Volume:
1.78
Capitalizzazione di mercato:
$52.39B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-162.67
EPS:
-2.47
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+22.20%
1M Prestazione:
+24.76%
6M Prestazione:
+48.10%
1 anno Prestazione:
+49.58%
Intervallo 1D:
Value
$382.19
$401.80
Intervallo di 1 settimana:
Value
$323.74
$402.43
Portata 52W:
Value
$205.87
$402.43

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Nome
Alnylam Pharmaceuticals Inc
Name
Telefono
(617) 551-8200
Name
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Dipendente
2,230
Name
Cinguettio
@alnylam
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ALNY's Discussions on Twitter

Confronta ALNY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-30 Ripresa Raymond James Outperform
2025-07-21 Iniziato Truist Buy
2025-03-31 Iniziato Redburn Atlantic Buy
2025-03-24 Aggiornamento JP Morgan Neutral → Overweight
2024-11-12 Downgrade Wolfe Research Peer Perform → Underperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-08-16 Aggiornamento Goldman Neutral → Buy
2024-02-16 Downgrade Goldman Buy → Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-08 Iniziato Wells Fargo Equal Weight
2023-10-11 Downgrade Oppenheimer Outperform → Perform
2023-09-29 Iniziato Raymond James Outperform
2023-05-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-26 Iniziato SMBC Nikko Neutral
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Buy
2022-09-09 Ripresa Morgan Stanley Equal-Weight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-27 Downgrade Guggenheim Buy → Neutral
2022-06-07 Iniziato William Blair Outperform
2022-04-25 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-03-01 Iniziato Citigroup Buy
2022-02-03 Aggiornamento Guggenheim Neutral → Buy
2022-01-03 Aggiornamento Piper Sandler Neutral → Overweight
2021-11-22 Aggiornamento Goldman Neutral → Buy
2021-11-22 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Aggiornamento Oppenheimer Perform → Outperform
2021-10-04 Aggiornamento UBS Neutral → Buy
2021-08-04 Downgrade Piper Sandler Overweight → Neutral
2021-02-22 Downgrade Guggenheim Buy → Neutral
2021-02-12 Downgrade Citigroup Buy → Neutral
2021-02-12 Reiterato H.C. Wainwright Buy
2021-01-25 Downgrade BMO Capital Markets Outperform → Market Perform
2020-09-30 Ripresa Berenberg Hold
2020-09-08 Iniziato Citigroup Buy
2020-08-11 Downgrade Oppenheimer Outperform → Perform
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2020-05-07 Downgrade JP Morgan Overweight → Neutral
2020-04-24 Ripresa Evercore ISI Outperform
2020-03-19 Iniziato Berenberg Buy
2019-12-19 Reiterato Chardan Capital Markets Buy
2019-11-20 Iniziato Oppenheimer Outperform
2019-11-13 Iniziato BofA/Merrill Buy
2019-05-23 Ripresa Goldman Neutral
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-06 Aggiornamento Evercore ISI In-line → Outperform
2019-03-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-01-23 Iniziato UBS Neutral
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-13 Reiterato Stifel Buy
2018-08-07 Aggiornamento Stifel Hold → Buy
2018-05-04 Reiterato Stifel Hold
2018-03-28 Iniziato Evercore ISI In-line
Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

pulisher
07:40 AM

This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga

07:40 AM
pulisher
03:48 AM

Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st

03:48 AM
pulisher
Aug 03, 2025

When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Published on: 2025-08-03 13:52:50 - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 02, 2025

What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 01, 2025

BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals Sees Strong Sales of Rare Disease Drug, Raises Revenue Guidance - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance - AOL.com

Aug 01, 2025
pulisher
Aug 01, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Why Is Alnylam Stock Gaining Friday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam soars past $50B market cap - The Business Journals

Aug 01, 2025
pulisher
Aug 01, 2025

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - TradingView

Aug 01, 2025
pulisher
Aug 01, 2025

Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025
pulisher
Aug 01, 2025

Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress - Morningstar

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals Inc (ALNY) Q2 2025 Earnings Call Highlig - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus

Aug 01, 2025
pulisher
Jul 31, 2025

Alnylam: Q2 Earnings Snapshot - Norwalk Hour

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Soars 15.43% on $1.31B Trade Volume Surge as TTR Revenues Jump 64% and Raised 2025 Outlook - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Pharmaceuticals Surges 15.43% On Strong Technical Breakout - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Novartis wins FDA label update for Alnylam-partnered cholesterol drug - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches - insights.citeline.com

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - inkl

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam's Amvuttra: A Game-Changer in ATTR-CM and a Catalyst for Biotech Growth - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam: Amvuttra Is Just Getting Started (NASDAQ:ALNY) - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam reaches new highs on strong sales of closely watched rare disease drug - BioPharma Dive

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings call transcript: Alnylam’s Q2 2025 results boost stock by 18% - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates - Investing.com

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates By Investing.com - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Pharmaceuticals Surpasses Wall Street Expectations in Q2News and Statistics - IndexBox

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam jumps on full year revenue guidance raise (ALNY) - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Jul 31, 2025

Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$558.87
price up icon 2.46%
$673.80
price up icon 0.52%
biotechnology ONC
$299.01
price down icon 0.70%
$107.34
price down icon 0.15%
$27.07
price up icon 2.65%
Capitalizzazione:     |  Volume (24 ore):